Rhythm eyes a piv­otal test af­ter rolling through PhII with up­beat re­sults for rare obe­si­ty cas­es

Boston-based Rhythm can now boast about pub­lish­ing the re­sults of a new Phase II obe­si­ty drug study in the pres­ti­gious New Eng­land Jour­nal of Med­i­cine. The da­ta, while on­ly cov­er­ing two pa­tients, points to the po­ten­tial of their drug set­melan­otide for ex­treme­ly rare cas­es of pro-opi­ome­lanocortin (POMC) de­fi­cien­cy. And the biotech is mov­ing to a mid-stage read­out for an­oth­er pro­gram on Prad­er-Willi syn­drome, which just de­feat­ed Zaf­gen’s piv­otal ef­forts af­ter two pa­tients died in their study, as it sets the stage for a near-term piv­otal tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA